2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1241

Understanding Lupus Patients’ Ability to Work with Numbers

Health Services Research - Poster II

9:00AM-11:00AM: Abstract Number: 1345

Undifferentiated Connective Tissue Disease: A 121 Patients Audit Focusing on Initial Diagnosis and Changes over Time

Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

9:00AM-11:00AM: Abstract Number: 1685

Updated Results for All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1684

Updated Results for Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1865

Urinary Cell Adhesion Molecules As Markers of Renal Involvement in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster II

9:00AM-11:00AM: Abstract Number: 1322

Use of Biologics in Arthritis Patients with Hepatitis B and C ‏: A Multicentral Retrospective Case Series

Infection-related Rheumatic Disease - Poster

9:00AM-11:00AM: Abstract Number: 1342

Use of Immune Checkpoint Inhibitors in the Treatment of Patients with Cancer and Preexisting Autoimmune Diseases: A Systematic Review of Case Reports

Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

9:00AM-11:00AM: Abstract Number: 1159

Use of Rheumatology-Specific Patient Navigators for DMARD Adherence: Results from a Pilot Intervention

Education - ARHP Poster

9:00AM-11:00AM: Abstract Number: 1338

Use of Subcutaneous Golimumab in Autoimmune Inner Ear Disease

Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

9:00AM-11:00AM: Abstract Number: 1157

Using Goutpro to Make Medical Trainees Gout Pros

Education - ARHP Poster

9:00AM-11:00AM: Abstract Number: 1423

Using Self-Reported Patient Experiences to Evaluate Patient Reported Outcomes (PRO) Instruments: Learnings from Digital Patient Communities in Psoriatic Arthritis

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1426

Using Self-Reported Patient Experiences to Understand Patient Burden: Learnings from Digital Patient Communities in Ankylosing Spondylitis

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1707

Ustekinumab and the Comparative Risk for Acute Myocardial Infarction in Patients with Psoriasis and Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1718

Ustekinumab, Apremilast, TNFi and the Risk for Hospitalized Infection in Patients with Psoriasis and Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1293

Utility of Extremity Magnetic Resonance Imaging (eMRI) without Contrast Enhancement in Detecting Preclinical Psoriatic Arthritis

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].